Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
611 questions in 50 reviews · Injuries
current versionsNo studies 125 · 20.5%Ungraded 22 · 3.6%Very low 185 · 30.3%Low 171 · 28%Moderate 77 · 12.6%High 31 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
DDAVP vs aprotinin Blood loss (total) · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | NR | No studies |
DDAVP vs aprotinin All‐cause mortality · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | 1 study · 53 participants | Very low |
DDAVP vs aprotinin All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | 0.98 [0.06, 15.89] | 2 studies · 152 participants | Very low |
DDAVP vs aprotinin Quality of life · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | NR | No studies |
DDAVP vs placebo or standard care Blood loss (total) · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | 28 studies · 1643 participants | Very low |
DDAVP vs placebo or standard care All‐cause mortality · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | 1.09 [0.51, 2.34] | 22 studies · 1631 participants | Low |
DDAVP vs placebo or standard care All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | 1.36 [0.85, 2.16] | 29 studies · 1984 participants | Low |
DDAVP vs placebo or standard care Quality of life · participants undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | NR | No studies |
DDAVP vs placebo or standard care: platelet dysfunction subgroup Red cell volume transfused (total) · participants with platelet dysfunction undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | 6 studies · 388 participants | Low |
DDAVP vs placebo or standard care: platelet dysfunction subgroup Number of participants receiving a red cell transfusion (total) · participants with platelet dysfunction undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | RR 0.83 [0.66, 1.04] | 5 studies · 258 participants | Low |
DDAVP vs placebo or standard care: platelet dysfunction subgroup Blood loss (total) · participants with platelet dysfunction undergoing surgery Desmopressin use for minimising perioperative blood transfusion (2017) · Cochrane | no estimate extracted | 7 studies · 422 participants | Low |
Cardiorespiratory exercise programmes prescribed alone vs a non‐exercise intervention or no intervention Cardiorespiratory fitness ‐ peak power output (W) ‐ end of intervention · people with traumatic brain injury of any age or severity Fitness training for cardiorespiratory conditioning after traumatic brain injury (2017) · Cochrane | no estimate extracted | 3 studies · 67 participants | Low |
Cardiorespiratory exercise programmes prescribed alone vs a non‐exercise intervention or no intervention Depression ‐ SMD ‐ end of intervention · people with traumatic brain injury of any age or severity Fitness training for cardiorespiratory conditioning after traumatic brain injury (2017) · Cochrane | no estimate extracted | 4 studies · 220 participants | Very low |
Cardiorespiratory exercise programmes prescribed alone vs a non‐exercise intervention or no intervention Cognition · people with traumatic brain injury of any age or severity Fitness training for cardiorespiratory conditioning after traumatic brain injury (2017) · Cochrane | no estimate extracted | 2 studies · 111 participants | Ungraded |
Cardiorespiratory exercise programmes prescribed alone vs a non‐exercise intervention or no intervention Fatigue ‐ SMD ‐ end of intervention · people with traumatic brain injury of any age or severity Fitness training for cardiorespiratory conditioning after traumatic brain injury (2017) · Cochrane | no estimate extracted | 3 studies · 130 participants | Very low |
Cardiorespiratory exercise programmes prescribed alone vs a non‐exercise intervention or no intervention Community integration · people with traumatic brain injury of any age or severity Fitness training for cardiorespiratory conditioning after traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 76 participants | Ungraded |
Cardiorespiratory exercise programmes prescribed alone vs a non‐exercise intervention or no intervention Safety · people with traumatic brain injury of any age or severity Fitness training for cardiorespiratory conditioning after traumatic brain injury (2017) · Cochrane | no estimate extracted | 5 studies · 183 participants | Ungraded |
Baclofen vs placebo Spasticity at up to 6 hours after treatment (measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity) · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 11 participants | Low |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) Sensory functions and pain · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) Neuromusculoskeletal and movement‐related functions at 12 weeks (measured by ankle dorsiflexion) · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 2 studies · 47 participants | Very low |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) General tasks and demands · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) Mobility · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) Self‐care · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Pseudoelastic orthosis vs traditional (static) splint Spasticity at up to 6 hours after treatment (measured by the Modified Ashworth Scale, 0‐4, with a higher score indicating greater spasticity) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Pseudoelastic orthosis vs traditional (static) splint Adverse events · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Pseudoelastic orthosis vs traditional (static) splint Sensory functions and pain · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Pseudoelastic orthosis vs traditional (static) splint Neuromusculoskeletal and movement‐related functions post treatment (measured by range of movement) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Pseudoelastic orthosis vs traditional (static) splint General tasks and demands · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Baclofen vs placebo Adverse events · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 11 participants | Low |
Pseudoelastic orthosis vs traditional (static) splint Mobility · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Pseudoelastic orthosis vs traditional (static) splint Self‐care · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis'… Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Baclofen vs placebo Sensory functions and pain · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Baclofen vs placebo Neuromusculoskeletal and movement‐related functions up to 6 hours after treatment (Measured by spasm and deep tendon reflex scores, 0‐5, with 0 being no reflexes and 5 being clonus, or repeated involuntary muscle contractions) · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 1 study · 11 participants | Low |
Baclofen vs placebo General tasks and demands · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Baclofen vs placebo Mobility · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Baclofen vs placebo Self‐care · adults with traumatic brain injury with spasticity in their arms and legs Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) Spasticity at 4‐12 weeks (measured by both Modified Ashworth Scale, 0‐5, at 12 weeks and Tardieu Scale, 0‐5, at 4 weeks) · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 2 studies · 47 participants | Very low |
Botulinum toxin A (with and without casting) vs placebo (with and without casting) Adverse events · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) Interventions for managing skeletal muscle spasticity following traumatic brain injury (2017) · Cochrane | no estimate extracted | 2 studies · 47 participants | Very low |
Intervention NR Mortality · people with severe traumatic brain injury (adults and children) Elevation of the head during intensive care management in people with severe traumatic brain injury (2017) · Cochrane | no estimate extracted | 3 studies · 20 participants | Very low |
Intervention NR Intracranial pressure (ICP) · people with severe traumatic brain injury (adults and children) Elevation of the head during intensive care management in people with severe traumatic brain injury (2017) · Cochrane | no estimate extracted | 3 studies · 20 participants | Very low |
Intervention NR Cerebral perfusion pressure (CPP) · people with severe traumatic brain injury (adults and children) Elevation of the head during intensive care management in people with severe traumatic brain injury (2017) · Cochrane | no estimate extracted | 3 studies · 20 participants | Very low |
Intervention NR Quality of life; Glasgow Coma Score; Disability · people with severe traumatic brain injury (adults and children) Elevation of the head during intensive care management in people with severe traumatic brain injury (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · people with severe traumatic brain injury (adults and children) Elevation of the head during intensive care management in people with severe traumatic brain injury (2017) · Cochrane | no estimate extracted | 3 studies · 20 participants | Very low |
Intervention NR Mortality at end of scheduled · people with acute TBI secondary to head injury Progesterone for acute traumatic brain injury (2016) · Cochrane | RR 0.91 [0.65, 1.28] | 5 studies · 2376 participants | Low |
Intervention NR Disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1‐3) at end of scheduled · people with acute TBI secondary to head injury Progesterone for acute traumatic brain injury (2016) · Cochrane | RR 0.98 [0.89, 1.06] | 4 studies · 2260 participants | Moderate |
Intervention NR Intracranial pressure (ICP) within the treatment period · people with acute TBI secondary to head injury Progesterone for acute traumatic brain injury (2016) · Cochrane | no estimate extracted | 3 studies · 3 participants | Ungraded |
Intervention NR Blood pressure · people with acute TBI secondary to head injury Progesterone for acute traumatic brain injury (2016) · Cochrane | no estimate extracted | 1 study · 1 participants | Ungraded |
Intervention NR Body temperature · people with acute TBI secondary to head injury Progesterone for acute traumatic brain injury (2016) · Cochrane | no estimate extracted | 1 study · 1 participants | Ungraded |
Intervention NR Adverse events · people with acute TBI secondary to head injury Progesterone for acute traumatic brain injury (2016) · Cochrane | no estimate extracted | 4 studies · 4 participants | Ungraded |
School injury prevention programmes vs controls Self‐reported medically or non‐medically attended unintentional injuries or injuries with an unspecified intent (injury rates adjusted for clustering) · children and young people School‐based education programmes for the prevention of unintentional injuries in children and young people (2016) · Cochrane | Rate ratio 0.76 [0.49, 1.17] | 2 studies · 12977 participants | Low |